Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from A complementary dual-platform analytical strategy for resolving matrix effects and stability limitations in bioanalysis. Local targets link to admitted publications; unresolved targets remain external evidence.
Pharmacological and Pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the Practising physician
10.1053/bega.2001.0184 · 2001 · External reference
An updated review of its Pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases
1989 · External reference
Control of gastric acid secretion. Histamine H2-receptor antagonists and H+K(+)-ATPase inhibitors
10.1016/s0889-8553(21)00047-9 · 1992 · External reference
Pharmacokinetics and pharmacodynamics of the proton pump inhibitors
10.5056/jnm.2013.19.1.25 · 2013 · External reference
Unresolved reference
1983 · External reference
Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors
10.1021/ja049607w · 2004 · External reference
Proton pump inhibitors: new mechanisms of action
10.1111/bcpt.13237 · 2019 · External reference
Prevention of stress ulceration: current trends in critical care
10.1097/01.ccm.0000142398.73762.20 · 2004 · External reference
Pharmacology of gastric acid inhibition
10.1016/0950-3528(93)90030-v · 1993 · External reference
Omeprazole: pharmacology, pharmacokinetics and interactions
10.1159/000200098 · 1989 · External reference
Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors
10.1111/j.1572-0241.1998.221_a.x · 1998 · External reference
Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough
10.1111/j.1365-2036.2004.01949.x · 2004 · External reference
A comprehensive review on omeprazole: pharmacological effects and its adverse effects
10.55544/jrasb.4.1.4 · 2025 · External reference
Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions
10.1124/dmd.113.051722 · 2013 · External reference
Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype
10.1016/j.jphs.2019.03.001 · 2019 · External reference
Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-Oesophageal reflux disease
10.1111/j.1365-2036.2005.02468.x · 2005 · External reference
Suppression of nocturnal acid secretion with famotidine accelerates gastric ulcer healing
10.1016/0016-5085(89)91489-3 · 1989 · External reference
Famotidine: a notable lack of drug interactions
10.3109/00365528709090142 · 1987 · External reference
Can famotidine and omeprazole be combined on a once-daily basis?
10.1080/00365520601026665 · 2007 · External reference
The prevalence and anatomical distribution of equine gastric ulceration syndrome (EGUS) in 201 horses in Denmark
10.2746/042516409x441910 · 2009 · External reference
The prevalence and distribution of gastric ulceration in 345 racehorses
10.1111/j.1751-0813.2003.tb11469.x · 2003 · External reference
Equine gastric ulcer syndrome in adult horses: a review
10.1080/00480169.2007.36728 · 2007 · External reference
New perspectives in equine gastric ulcer syndrome
10.1016/j.cveq.2009.04.013 · 2009 · External reference
European College of Equine Internal Medicine Consensus Statement--Equine Gastric Ulcer Syndrome in adult horses
10.1111/jvim.13578 · 2015 · External reference
Improved selectivity in detection of polar basic drugs by liquid chromatography-electrospray ionization mass spectrometry. Illustration using an assay method for the determination of famotidine in human plasma
2001 · External reference
Determination of famotidine in low-volume human plasma by Normal-phase liquid chromatography/tandem mass spectrometry
10.1002/jms.176 · 2001 · External reference
Quantitative determination of famotidine in human maternal plasma, umbilical cord plasma and urine using high-performance liquid chromatography-mass spectrometry
10.1002/bmc.2873 · 2013 · External reference
Different effects of proton pump inhibitors and famotidine on the Clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4
10.3109/00498254.2011.653655 · 2012 · External reference
Sensitive quantification of omeprazole and its metabolites in human plasma by liquid chromatography-mass spectrometry
10.1016/j.jchromb.2005.11.036 · 2006 · External reference
Novel LC-MS/MS method for quantification of famotidine and metoprolol and application to pharmacokinetic interaction
10.1002/bmc.70114 · 2025 · External reference
A column-switching method for quantification of the enantiomers of omeprazole in native matrices of waste and estuarine water samples
10.1016/j.talanta.2010.04.056 · 2010 · External reference
Spectrophotometric methods for the determination of omeprazole in bulk form and pharmaceutical formulations
10.1016/s0039-9140(97)83117-7 · 1997 · External reference
Green synthesis of silver nanoparticles in deep eutectic solvent and their application in an electrochemical sensor for famotidine determination in pharmaceutical and biological samples
10.1016/j.talanta.2025.128779 · 2026 · External reference
Application of Polyacrylonitrile nanofibers decorated with magnetic carbon dots as a resonance light scattering sensor to determine famotidine
10.1016/j.talanta.2018.01.021 · 2018 · External reference
Square wave adsorptive stripping Voltammetric determination of famotidine in urine
10.1016/j.talanta.2005.01.017 · 2005 · External reference
Capillary zone electrophoresis method for the determination of famotidine and related impurities in pharmaceuticals
10.1016/j.talanta.2007.06.036 · 2008 · External reference
Comparative validations of non-aqueous capillary electrophoresis and high-performance liquid chromatography methods for the simultaneous determination of histamine H2 receptor antagonists in human urine
10.1016/j.jchromb.2013.01.020 · 2013 · External reference
High-throughput screening of corticosteroids and basic drugs in horse urine by liquid chromatography-tandem mass spectrometry
10.1016/j.jchromb.2004.12.039 · 2005 · External reference
Study of the effect of CYP2C19 polymorphisms on omeprazole pharmacokinetics by utilizing validated LC-MS/MS and real time-Pcr methods
10.1016/j.jchromb.2016.06.046 · 2017 · External reference
Simultaneous determination of tolbutamide, omeprazole, midazolam and dextromethorphan in human plasma by LC-MS/MS--a high throughput approach to evaluate drug-drug interactions
10.1016/j.jchromb.2010.03.026 · 2010 · External reference
The comparative effects of single intravenous doses of omeprazole and famotidine on intragastric pH
10.1007/s00535-003-1240-6 · 2004 · External reference
Retention behaviour of analytes in reversed-phase high-performance liquid chromatography-a review
10.1002/bmc.5482 · 2023 · External reference
Hplc method development and validation: a review
10.7897/2230-8407.04407 · 2016 · External reference
The influence and compensation of environmental factors (pH, temperature, and conductivity) on the detection of chemical oxygen demand in water by UV-vis spectroscopy
10.3390/app15041694 · 2025 · External reference
Buffer capacities of human blood and plasma
10.1093/clinchem/4.6.452 · 1958 · External reference
Development and validation of a novel stability-indicating RP-HPLC method for the simultaneous determination of related substances of Ketoprofen and omeprazole in combined capsule dosage form
10.1093/chromsci/bmw008 · 2016 · External reference
Design of Experiment (DOE) utilization to develop a simple and robust reversed-phase HPLC technique for related substances' estimation of omeprazole formulations
10.3797/scipharm.1306-06 · 2013 · External reference
Identification and structural characterization of the stress degradation products of omeprazole using Q-Tof-LC-ESI-MS/MS and NMR experiments: evaluation of the toxicity of the degradation products
10.1039/c9nj00932a · 2019 · External reference
Determination of omeprazole and its related impurities in bulk drug substance batches by a stability indicating HPLC method based on a short octyl fused core column
10.1007/s10337-025-04418-3 · 2025 · External reference
Development and validation of a stability indicating method for the enantioselective estimation of omeprazole enantiomers in the enteric-coated formulations by high-performance liquid chromatography
10.4103/0975-7406.80766 · 2011 · External reference
Kinetics of omeprazole degradation in solid state
2011 · External reference
Stability of omeprazole solutions at various pH values as determined by high-performance liquid chromatography
10.3109/03639049509026660 · 1995 · External reference
Re-evaluation of the regulation of omeprazole in racehorses: an evidence-based approach
10.1111/jvp.12491 · 2018 · External reference
Acid-neutralizing omeprazole formulation for rapid release and absorption
10.3390/pharmaceutics17020161 · 2025 · External reference
Absolute bioavailability and metabolism of omeprazole in relation to Cyp2c19 genotypes following single intravenous and Oral administrations
10.1007/s00228-006-0251-7 · 2007 · External reference
The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses
10.1097/00007691-199003000-00010 · 1990 · External reference
